PHS
HALO icon

PFM Health Sciences’s Halozyme HALO Stock Holding History

PFM Health Sciences’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-597,545
Closed -$16M – 84
2020
Q2 		$16M Sell
597,545
-21,181
-3% -$478K 0.83% 46
2020
Q1 		$11.1M Buy
618,726
+25,246
+4% +$479K 0.91% 39
2019
Q4 		$10.5M Buy
+593,480
New +$10.3M 0.5% 47

Other funds holding HALO

Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

PFM Health Sciences's HALO Position: Q3 2020 in Review

PFM Health Sciences sold out of Halozyme (HALO) in Q3 2020, closing a stake of 597,545 shares — an estimated $16M sold.

PFM Health Sciences first reported a position in HALO in Q4 2019 and held it in 3 quarters. The position peaked at $16M in Q2 2020. 268 funds tracked by Wall St. Rank hold HALO as of Q3 2020.

  • PFM Health Sciences reported no remaining Halozyme position as of Q3 2020 after selling out during the quarter.
  • PFM Health Sciences sold 597,545 Halozyme shares in Q3 2020, an estimated $16M.
  • PFM Health Sciences first reported a position in Halozyme in Q4 2019 and held it in 3 quarters.
  • PFM Health Sciences's Halozyme position peaked at $16M in Q2 2020.
  • 268 funds tracked by Wall St. Rank held Halozyme as of Q3 2020.

Based on PFM Health Sciences's 13F filing for Q3 2020, filed 16 Nov 2020.